{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:14:09Z","timestamp":1774332849244,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Some controversy remains regarding conventional serum indices for the evaluation of liver fibrosis. Therefore, we aimed to combine the existing index with other serum parameters to discriminate liver fibrosis stages in patients with chronic hepatitis B (CHB).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>A total of 1,622 treatment-na\u00efve CHB patients were divided into training (<jats:italic>n<\/jats:italic>= 1,211) and validation (<jats:italic>n<\/jats:italic>= 451) cohorts. Liver histology was assessed according to the Scheuer scoring scheme. All common demographic and clinical parameters were analyzed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>By utilizing the results of the logistic regression analysis, we developed a novel index, the product of GPR, international normalized ratio (INR), and type IV collagen (GIVPR), to discriminate liver fibrosis. In the training group, the areas under the ROCs (AUROCs) of GIVPR, APRI, FIB-4, and GPR for significant fibrosis were 0.81, 0.75, 0.72, and 0.77, respectively; the AUROCs of GIVPR, APRI, FIB-4, and GPR for advanced fibrosis were 0.82, 0.74, 0.74, and 0.78, respectively; and the AUROCs of GIVPR, APRI, FIB-4, and GPR for cirrhosis were 0.87, 0.78, 0.78, and 0.83, respectively. Similar results were also obtained in the validation group. Furthermore, the decision curve analysis suggested that GIVPR represented superior clinical benefits in both independent cohorts.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>The GIVPR constructed on GPR represents a superior predictive model for discriminating liver fibrosis in CHB patients.<\/jats:p>","DOI":"10.3389\/fmed.2021.727706","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T07:55:00Z","timestamp":1632383700000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["A Novel Non-invasive Model Based on GPR for the Prediction of Liver Fibrosis in Patients With Chronic Hepatitis B"],"prefix":"10.3389","volume":"8","author":[{"given":"Rongrong","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0152757","DOI":"10.1371\/journal.pone.0152757","article-title":"The diagnostic accuracy and clinical utility of three noninvasive models for predicting liver fibrosis in patients with HBV infection","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS ONE."},{"key":"B6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jgh.13811","article-title":"Stepwise application of fibrosis index based on four factors, red cell distribution width-platelet ratio, and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection","volume":"33","author":"Chen","year":"2018","journal-title":"J Gastroenterol Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ajg.2010.463","article-title":"Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B","volume":"106","author":"Fung","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/MEG.0000000000001599","article-title":"Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C","volume":"32","author":"Gozdas","year":"2020","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e6336","DOI":"10.1097\/MD.0000000000006336","article-title":"Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT <\/= 2 ULN: a retrospective cohort study","volume":"96","author":"Li","year":"2017","journal-title":"Medicine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/gutjnl-2015-309260","article-title":"The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa","volume":"65","author":"Lemoine","year":"2016","journal-title":"Gut."},{"key":"B11","doi-asserted-by":"publisher","first-page":"28641","DOI":"10.18632\/oncotarget.16162","article-title":"The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1177\/0300060516664638","article-title":"Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients","volume":"44","author":"Wang","year":"2016","journal-title":"J Int Med Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1038\/s41598-017-09234-w","article-title":"Gamma-glutamyl-transpeptidase to platelet ratio is not superior to APRI,FIB-4 and RPR for diagnosing liver fibrosis in CHB patients in China","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep."},{"key":"B14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2460\/ajvr.1998.59.03.340","article-title":"Effect of ischemia and reperfusion on oxidative processes in the large colon and jejunum of horses","volume":"59","author":"Kooreman","year":"1998","journal-title":"Am J Vet Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12072-011-9328-1","article-title":"Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B","volume":"6","author":"Wu","year":"2012","journal-title":"Hepatol Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment","volume":"13","author":"Scheuer","year":"1991","journal-title":"J Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-016-9760-3","article-title":"Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update","volume":"11","author":"Shiha","year":"2017","journal-title":"Hepatol Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cld.2008.07.010","article-title":"Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities","volume":"12","author":"Guha","year":"2008","journal-title":"Clin Liver Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/alcalc\/37.3.252","article-title":"Effects of alcohol consumption on eight circulating markers of liver fibrosis","volume":"37","author":"Ponomarenko","year":"2002","journal-title":"Alcohol Alcohol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/hep.24013","article-title":"Noninvasive assessment of liver fibrosis","volume":"53","author":"Martinez","year":"2011","journal-title":"Hepatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/MEG.0000000000000298","article-title":"Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study","volume":"27","author":"El-Mezayen","year":"2015","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/liv.13393","article-title":"Are non-invasive fibrosis markers for chronic hepatitis B reliable in sub-Saharan Africa?","volume":"37","author":"Desalegn","year":"2017","journal-title":"Liver Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.dld.2007.10.011","article-title":"Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B","volume":"40","author":"Shin","year":"2008","journal-title":"Dig Liver Dis."},{"key":"B29","volume-title":"Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection","year":"2015"},{"key":"B30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hep.27382","article-title":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis","volume":"61","author":"Xiao","year":"2015","journal-title":"Hepatology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/gutjnl-2016-311554","article-title":"Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio (GPR) using transient elastography as a reference","volume":"66","author":"Lemoine","year":"2017","journal-title":"Gut."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/gutjnl-2016-312658","article-title":"The gamma-glutamyl transpeptidase to platelet ratio (GPR) in HBV patients: just adding up?","volume":"66","author":"Schiavon","year":"2017","journal-title":"Gut."},{"key":"B33","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/jvh.12224","article-title":"The validity of serum markers for fibrosis staging in chronic hepatitis B and C","volume":"21","author":"Li","year":"2014","journal-title":"J Viral Hepat."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001973","article-title":"Development and evaluation of a novel noninvasive index for predicting significant fibrosis, advanced fibrosis, and cirrhosis in patients with chronic hepatitis B infection","author":"Kayadibi","year":"2020","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/MEG.0b013e32830dfcb3","article-title":"King's Score: an accurate marker of cirrhosis in chronic hepatitis C","volume":"21","author":"Cross","year":"2009","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/jvh.13174","article-title":"HEV-LFS: a novel scoring model for patients with hepatitis E virus-related liver failure","volume":"26","author":"Wu","year":"2019","journal-title":"J Viral Hepat."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.cca.2010.04.009","article-title":"Circulating markers of liver fibrosis progression","volume":"411","author":"Jarcuska","year":"2010","journal-title":"Clin Chim Acta."},{"key":"B38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0168-8278(95)80328-9","article-title":"Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis","volume":"23","author":"Murawaki","year":"1995","journal-title":"J Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0168-8278(96)80027-4","article-title":"Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases","volume":"24","author":"Ueno","year":"1996","journal-title":"J Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.727706\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T18:51:30Z","timestamp":1725821490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.727706\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":39,"alternative-id":["10.3389\/fmed.2021.727706"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.727706","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"article-number":"727706"}}